3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
5
Ovarian Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Urogenital Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Neoplastic Syndromes, Hereditary
1
Neoplasms, Unknown Primary
1
Melanoma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Digestive System Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Brain Neoplasms
1
Interventions
pembrolizumab
44
Cyclophosphamide
21
Nivolumab
18
fludarabine
10
durvalumab
8
Paclitaxel
8
Magnetic Resonance Spectroscopy
8
Interleukin-2
8
Docetaxel
8
aldesleukin
7
Radiosurgery
7
Ipilimumab
7
spartalizumab
6
poly ICLC
6
fludarabine phosphate
6
atezolizumab
6
Specimen Handling
6
Radiotherapy
6
Carboplatin
6
cemiplimab
5
Drug Therapy
5
Cisplatin
5
Biopsy
5
Temozolomide
4
Immune Checkpoint Inhibitors
4
tremelimumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
3
pazopanib
3
avelumab
3
Trastuzumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Genetic Counseling
×
Breast
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled